|
FOR RELEASE ON |
20 September 2022 |
IP Group plc - Director/PDMR Shareholding
IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, announces that, further to the announcements dated 03 August 2022, 18 August 2022, 13 September 2022 and 14 September 2022 in connection with the Interim Scrip Dividend, a combined total of 3,408 new ordinary shares of 2p each ("Shares") in aggregate have been allotted to one of the Group's executive directors and four of its persons discharging managerial responsibilities ("PDMRs"), following their respective elections to take up the Interim Scrip Dividend in relation to some or all of their current shareholdings, as further detailed below.
Shares in issue
The Group currently has 1,063,188,005 Shares in issue and 28,607,622 Shares held in Treasury.
The following information is being disclosed pursuant to the requirements of MAR.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Scrip Election
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||||||||||||||||||
|
a) |
Name(s) |
Greg Smith Heejae Chae Christopher Glasson Angela Leach Lisa Patel |
|||||||||||||||||||||
|
2 |
Reason for the notification |
||||||||||||||||||||||
|
a) |
Position/status |
Executive Director Chief Executive Officer PDMR Non-Executive Director PDMR Finance Director PDMR Group General Counsel PDMR Partner, Life Sciences
|
|||||||||||||||||||||
|
|
Initial notification /Amendment |
Initial Notification |
|||||||||||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||||||||||||||
|
a) |
Name |
IP Group plc |
|||||||||||||||||||||
|
b) |
Legal Entity Identifier |
213800HG22UM138WFG43 |
|||||||||||||||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||||||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 2p each in IP Group plc |
|||||||||||||||||||||
|
b) |
Nature of the transaction |
Election of Scrip Dividend |
|||||||||||||||||||||
|
c) |
Currency |
GBP |
|||||||||||||||||||||
|
d) |
Price(s) and volume(s) |
|
|||||||||||||||||||||
|
e) |
Aggregated information -Aggregated volume - Price - Aggregated total |
Aggregated Number of Shares: 3,408 Price: 80.5p Aggregated Total: £2,743.44 |
|||||||||||||||||||||
|
f) |
Date of the transaction |
20 September 2022 |
|||||||||||||||||||||
|
g) |
Place of the transaction |
London Stock Exchange, Main Market
|
|||||||||||||||||||||
For more information, please contact:
|
IP Group plc |
|
|
David Baynes, Chief Financial and Operating Officer |
+44 (0) 20 7444 0050 |
Notes for editors
About IP Group
IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
For more information, please visit our website at www.ipgroupplc.com.
ENDS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
